In multivariate analysis , high tissue mRNA of angiogenic VEGF-Axxxa in the presence of bevacizumab therapy predicted for favorable progression-free survival ( HR for progression , 0.39 ; P = .0227 ) and OS ( HR for death , 0.32 ; P = .0140 ) .